Price
No data yet.
Social Signal Score
Revenue
$440.93B-11.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Tetsuji Kawamura
- Sector
- Technology
- Industry
- Consumer Electronics
- Employees
- 34,549
- Beta
- 0.70
- Country
- JP
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.88
Financials
Revenue
$440.93B-11.2%Net Income
$3.16BEBITDA
$17.67B+176.4%Free Cash Flow
$-24.79B-327.2%EPS (diluted)
$1.21Shares Outstanding (diluted)
2.60B-4.0%Operating Expenses
$93.83BCash & Debt
$248.70BReturn of Capital
$0.00Dividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $2.01T | $50.30B | $19.17 |
| 2025 | $2.16T | $36.09B | $13.90 |
| 2024 | $2.32T | $-149.98B | $-57.75 |
| 2023 | $2.55T | $-260.84B | $-101.83 |
| 2022 | $2.50T | $73.99B | $30.29 |
| 2021 | $2.43T | $53.26B | $21.80 |
| 2020 | $2.27T | $20.96B | $2.47 |
| 2019 | $2.40T | $74.23B | $7.60 |
| 2018 | $2.43T | $70.22B | $7.19 |
| 2017 | $2.05T | $-24.88B | $-2.54 |
| 2016 | $2.46T | $-255.97B | $-94.62 |
| 2015 | $2.79T | $-222.35B | $-82.19 |
| 2014 | $2.93T | $11.56B | $5.06 |
| 2013 | $2.48T | $-545.35B | $-306.14 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $28.45
- Implied price
- $199.18
- Return from $0.97
- 190.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $99.03 — today's price is already 99.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 3 | 5 | 7 | 9 | 11 |
|---|---|---|---|---|---|
| -2.0% | 122.2% | 146.1% | 163.2% | 176.8% | 188.1% |
| 3.0% | 133.5% | 158.6% | 176.6% | 190.9% | 202.8% |
| 8.0% | 144.8% | 171.2% | 190.1% | 205.0% | 217.5% |
| 13.0% | 156.2% | 183.7% | 203.5% | 219.1% | 232.2% |
| 18.0% | 167.5% | 196.3% | 216.9% | 233.3% | 246.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
97+20.83%Social Signal Score
Mentions (7)
- News247wallst.com·6d ago·Neutral
AMC Sinks 7%, Gives Back Part of Sharp Rally; Cinemark and IMAX Dip Selling is landing hard on AMC Entertainment (NYSE:AMC) stock as the theater chain is giving back part of a sharp rally from the prior session. AMC stock is at $3.05, down 7% in afternoon trading.
View source ↗ - News247wallst.com·7d ago·Neutral
Bloom Energy Sinks 8% as Sharp Run Unwinds; Plug Power Drops 6%, FuelCell Eases Fuel cell stocks are cooling off after a steep climb, and Bloom Energy (NYSE:BE) is taking the biggest hit in the group. Bloom Energy stock is down 8% to $265.
View source ↗ - News247wallst.com·11d ago·Positive
Arm Climbs 5% as Buyers Return After Sharp Pullback; Qualcomm Nudges Higher, Intel Sits Out the Rally Chip buyers are stepping back into Arm Holdings (NASDAQ:ARM | ARM Price Prediction) stock. The rebound follows a steep drop and is running well ahead of the rest of the semiconductor group.
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
Coach's Momentum Powers Tapestry Despite the Stock's Sharp Pullback Tapestry TodayTPRTapestry$113.77 -1.23 (-1.07%) As of 01:15 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$93.00▼$164.80Dividend Yield1.63%P/E Ratio15.61Price Target$175.13Add to WatchlistTapestry NYSE: TPR has spent the past two years rebuilding, and by many measures, the rebuild is working.
View source ↗ - Newsnewsfilecorp.com·38d ago·Neutral
Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its unaudited condensed interim consolidated financial statements for the six-month period ended June 30, 2026, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stat
View source ↗ - Newswsj.com·54d ago·Neutral
Cisco Reports Sharp Jump in Profit as AI Orders Roll In “Customers know that if they pause or slow down they run the risk of being way behind,” Chief Executive Chuck Robbins said.
View source ↗ - Newsseekingalpha.com·55d ago·Negative
Marvell: Don't Get Shaken Out Of The Sharp Sell-Off Marvell benefits from exponential AI data center growth and leadership in 1.6T optical networking chips. Custom chip programs, including Microsoft Maia 300 and CXL memory expansion, are driving new revenue streams. Severe optical device supply tightness is supporting a 10-20% pricing hike through CY27, but the risk is that the impact on gross margins is probably priced in.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $0.02 per share
Typical surprise +102.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$0.01 vs $0.01miss
- Mon, May 11$-0.05 vs $-0.01miss
- Fri, Feb 6$0.06 vs $0.03beat
- Tue, Nov 11$0.05 vs $0.02beat
- Fri, Aug 8$0.04 vs $0.02beat
- Mon, May 12$0.10 vs $0.03beat
Estimates and results for SHCAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in SHCAY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.